Merck's Ford-Hutchinson elected to Inovio SAB
This article was originally published in Scrip
Dr Anthony Ford-Hutchinson has joined the scientific advisory board of vaccines company Inovio Pharmaceuticals. Dr Ford-Hutchinson has over 30 years' experience in vaccine development and commercialisation, and retired from Merck & Co last month having served as senior vice-president of vaccines research and development and chair of the board for MSD Wellcome Trust Hilleman Labs.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.